This brochure highlights the HiXCap™ novel cap analog from Hongene Biotech.
Through its innovative chemical structure design, this product is engineered to address a key challenge in mRNA drug development: maintaining efficient mRNA translation under immune stress conditions. The brochure indicates that HiXCap™ effectively evades host cell immune suppression, thereby enhancing the protein expression levels of therapeutic mRNA.
All HiXCap™ products undergo stringent quality control, including Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR), and High-Performance Liquid Chromatography (HPLC), ensuring a purity of >99%, no significant impurities, and low endotoxin levels.
(For detailed information such as the scientific rationale, experimental data, and specific quality control standards, please download the complete brochure.)